Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: A JGOG study

International Journal of Gynecological Cancer

Volumn 20, Issue 2, 2010, Pages 240-247

  Takakura, Satoshi ^a   Takano, Masashi ^b   Takahashi, Fumiaki ^c   Saito, Toshiaki ^d   Aoki, Daisuke ^e   Inaba, Noriyuki ^f   Noda, Kiichiro ^g   Sugiyama, Toru ^h   Ochiai, Kazunori ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^c KITASATO UNIVERSITY   (Japan)

^d NATIONAL KYUSHU CANCER CENTER   (Japan)

^e KEIO UNIVERSITY   (Japan)

^f DOKKYO MEDICAL UNIVERSITY   (Japan)

^g KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

Carboplatin; Cisplatin; Clear cell adenocarcinoma; Irinotecan hydrochloride; Ovarian cancer; Paclitaxel

Indexed keywords

CARBOPLATIN; CISPLATIN; CORTICOSTEROID DERIVATIVE; DEXAMETHASONE; DIPHENHYDRAMINE; FAMOTIDINE; IRINOTECAN; PACLITAXEL; RANITIDINE; SEROTONIN 3 ANTAGONIST; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLEAR CELL CARCINOMA; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPEN STUDY; OVARIECTOMY; OVARY ADENOCARCINOMA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING; ADENOCARCINOMA; COMPARATIVE STUDY; MIDDLE AGED; OVARY TUMOR; TREATMENT OUTCOME;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARBOPLATIN; CISPLATIN; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL; TREATMENT OUTCOME;

EID: 77951922462     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181cafb47     Document Type: Article

References (20)

1. Sugiyama T, Kamura T, Kigawa J, et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer. 2000;88:2584-2589.
2. Takakura S, Saito M, Ueda K, et al. Irinotecan hydrochloride (CPT-11) and cisplatin as first-line chemotherapy after initial surgery for ovarian clear cell adenocarcinoma. Int Surg. 2007;92:202-208.
3. Kita T, Kikuchi Y, Kudoh K, et al. Exploratory study of effective chemotherapy to clear cell carcinoma of the ovary. Oncol Rep. 2000;7:327-331.
4. Goff BA, Sainz de la Cuesta R, Muntz HG, et al. Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol. 1996;60:412-417.
5. Rubin SC, Wong GY, Curtin JP, et al. Platinum-based chemotherapy of high-risk stage I epithelial ovarian cancer following comprehensive surgical staging. Obstet Gynecol. 1993;82:143-147.
6. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334:1-6.
7. Piccart MJ, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst. 2000;92:699-708.
8. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21:3194-3200.
9. Enomoto T, Kuragaki C, Yamasaki M, et al. Is clear cell carcinoma and mucinous carcinoma of the ovary sensitive to combination chemotherapy with paclitaxel and carboplatin? Proc Am Soc Clin Oncol. 2003;22:447 [abstr 1797].
10. Ho CM, Huang YJ, Chen TC, et al. Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum based chemotherapy in pure-type advanced disease. Gynecol Oncol. 2004;94:197-203.
11. Utsunomiya H, Akahira J, Tanno S, et al. Paclitaxel-platinum combination chemotherapy for advanced or recurrent ovarian clear cell adenocarcinoma: a multicenter trial. Int J Gynecol Cancer. 2006;16:52-56.
12. Ho CM, Chien TY, Shih BY, et al. Evaluation of complete surgical staging with pelvic and para-aortic lymphadenectomy and paclitaxel plus carboplatin chemotherapy for improvement of survival in stage I ovarian clear cell carcinoma. Gynecol Oncol. 2003;88:394-399.
13. Takano M, Kikuchi Y, Yaegashi N, et al. Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging. Br J Cancer. 2006;94:1369-1374.
14. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002;346:85-91.
15. Sugiyama T, Yakushiji M, Nishida T, et al. Irinotecan (CPT-11) combined with cisplatin in patients with refractory or recurrent ovarian cancer. Cancer Lett. 1998;128:211-218.
16. Adachi S, Ogasawara T, Yamasaki N, et al. A pilot study of CPT-11 and cisplatin for ovarian clear cell adenocarcinoma. Jpn J Clin Oncol. 1999;29:434-437.
17. Takano M, Kikuchi Y, Yaegashi N, et al. Adjuvant chemotherapy with irinotecan hydrochloride and cisplatin for clear cell carcinoma of the ovary. Oncol Rep. 2006;16:1301-1306.
18. Sugiyama T, Yakushiji M, Kamura T, et al. Irinotecan (CPT-11) and cisplatin as first-line chemotherapy for advanced ovarian cancer. Oncology. 2002;63:16-22.
19. du Bois A, Lück HJ, Meier W, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst. 2003;95:1320-1329.
20. Takano M, Sugiyama T, Yaegashi N, et al. Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis. Int J Clin Oncol. 2007;12:256-260.